MetaCap

Biofrontera (BFRI) vs Chemomab Therapeutics (CMMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biofrontera (BFRI) has outperformed Chemomab Therapeutics (CMMB) over the past year, losing 28.4% versus a loss of 53.0%. Over five years, CMMB leads with a -96.6% price change compared with -99.7% for BFRI. Chemomab Therapeutics is the larger company by market cap ($9.6 million vs $9.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BFRI-28.38%CMMB-52.96%
+126%+29%-69%
Nov 21, 20251 yearNov 20, 2026
BFRI-99.01%CMMB-96.77%
+418%+147%-124%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BFRI versus CMMB key metrics
MetricBFRICMMB
Share price$0.53$1.19
Market cap$9.51M$9.58M
1-day change-7.02%+4.39%
YTD return-7.02%-27.88%
1-year return-28.38%-52.96%
5-year return-99.66%-96.65%
Forward P/E1.32—
EPS (TTM)$-0.26$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.70M—
Revenue growth (YoY)+11.75%—
Net income (latest FY)$-10.54M$-8.99M
Operating margin-27.21%—
Net margin-25.26%—
52-week high$1.66$2.99
52-week low$0.53$0.92
Distance from 52-week high-68.07%-60.20%
Analyst consensusnonenone
Avg. price target upside+1032.08%+320.17%
Average volume429.04K102.39K
Shares outstanding17.95M8.05M
Employees84—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BFRI has outperformed CMMB by 24.6 percentage points over the past year.

About Biofrontera

BFRI stock →

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About Chemomab Therapeutics

CMMB stock →

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations

BFRI vs CMMB FAQ

Which is bigger, Biofrontera or Chemomab Therapeutics?

Chemomab Therapeutics (CMMB) is larger, with a market capitalization of $9.58M compared with $9.51M for Biofrontera (BFRI).

Which stock has performed better over the past year, BFRI or CMMB?

BFRI returned -28.38% over the past 12 months, compared with -52.96% for CMMB (price return, excluding dividends). Past performance does not predict future results.

Are Biofrontera and Chemomab Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons